Degarelix as a neoadjuvant hormonal therapy for acute urinary tract toxicity associated with external beam radiotherapy for intermediate- and high-risk prostate cancer: a propensity score matched analysis.

CONCLUSIONS: Luteinizing hormone-releasing hormon antagonists may reduce acute urinary tract toxicity during prostate cancer external beam radiotherapy compared with luteinizing hormone-releasing hormon agonists, in particular in patients with moderate to severe symptoms at the start of treatment. PMID: 32875317 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32875317?dopt=Abstract

Source: Clinical Prostate Cancer - September 1, 2020 Category: Cancer & Oncology Authors: Hata S, Shin T, Abe S, Kawano K, Sato R, Kai T, Shibuya T, Ando T, Mimata H Tags: Jpn J Clin Oncol Source Type: research